Trials / Completed
CompletedNCT01257516
An Investigation Of The Absorption And Pharmacokinetics Of Multiple Doses Of A Controlled Release Pregabalin Tablet As Compared To Multiple Doses Of The Immediate Release Pregabalin Capsule In Healthy Volunteers
An Open-Label, Multiple-Dose, Randomized, 2-Way Crossover Study In Healthy Volunteers To Determine The Steady-State Pharmacokinetics Of 660 Mg (2 X 330 Mg Tablets) Pregabalin Controlled Release Formulation Administered Following An Evening Meal Relative To The 300 Mg Of The Immediate Release Formulation Administered Twice Daily
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to 1)evaluate the extent of absorption of multiple doses of a pregabalin controlled release tablet as compared to multiple doses of the pregabalin immediate release capsule, 2) evaluate the pharmacokinetics of multiple doses of a pregabalin controlled release tablet as compared to multiple doses of pregabalin immediate release capsule and 3) evaluate the safety and tolerability of multiple doses of a pregabalin controlled release tablet as compared to multiple doses of the pregabalin immediate release capsule.
Detailed description
Evaluate the absorption, pharmacokinetics, safety/tolerability of multiple doses of a pregabalin controlled release tablet as compared to multiple doses of pregabalin immediate release capsule
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pregabalin immediate release, 300 mg | 300 mg immediate release capsule administered twice daily for four days |
| DRUG | Pregabalin controlled release, 330 mg | Two tablets of 330 mg (total dose of 660 mg) given concurrently once daily for four days |
Timeline
- Start date
- 2011-02-01
- Primary completion
- 2011-03-01
- Completion
- 2011-03-01
- First posted
- 2010-12-09
- Last updated
- 2021-01-22
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT01257516. Inclusion in this directory is not an endorsement.